A Director at NeoGenomics (NASDAQ: NEO) is Selling Shares

By Carrie Williams

Today, a Director at NeoGenomics (NEOResearch Report), Kevin C. Johnson, sold shares of NEO for $1.12M.

Following Kevin C. Johnson’s last NEO Sell transaction on January 04, 2017, the stock climbed by 7.7%. In addition to Kevin C. Johnson, one other NEO executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on NeoGenomics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $69.1 million and quarterly net profit of $2.02 million. In comparison, last year the company earned revenue of $63.05 million and had a GAAP net loss of $5.1 million. NEO’s market cap is $1.55B and the company has a P/E ratio of 180.17. Currently, NeoGenomics has an average volume of 204.6K.

Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $20.00, reflecting a 20.1% upside.

In the last 30 days, insiders have sold $1.12M worth of NEO shares and purchased $46K worth of NEO shares. The insider sentiment on NeoGenomics has been positive according to 25 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services.